Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review Report H2 2016 - Research and Markets

Research and Markets
Posted on: 19 Sep 16

Research and Markets has announced the addition of the "Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016" drug pipelines to their offering.

'Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H2 2016'; pipeline Target constitutes close to 25 molecules. Out of which approximately 15 molecules are developed by Companies and remaining by the Universities Institutes.

Furthermore, the publisher says: Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.

'Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H2 2016' outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Nuclear Factor Erythroid 2 Related Factor 2 Overview
  3. Therapeutics Development
  4. Pipeline Products for Nuclear Factor Erythroid 2 Related Factor 2 - Overview
  5. Pipeline Products for Nuclear Factor Erythroid 2 Related Factor 2 - Comparative Analysis
  6. Nuclear Factor Erythroid 2 Related Factor 2 - Therapeutics under Development by Companies
  7. Nuclear Factor Erythroid 2 Related Factor 2 - Therapeutics under Investigation by Universities/Institutes
  8. Nuclear Factor Erythroid 2 Related Factor 2 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Nuclear Factor Erythroid 2 Related Factor 2 - Products under Development by Companies
  13. Nuclear Factor Erythroid 2 Related Factor 2 - Products under Investigation by Universities/Institutes
  14. Nuclear Factor Erythroid 2 Related Factor 2 - Companies Involved in Therapeutics Development
  • BioApex, s.r.o.
  • C4X Discovery Holdings PLC
  • Catabasis Pharmaceuticals, Inc.
  • Evgen Pharma Plc
  • Ixchel Pharma, LLC
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Reata Pharmaceuticals, Inc.
  • Rigel Pharmaceuticals, Inc.
  • XenoPort, Inc.

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/6h576b/nuclear_factor

Related Topics: Nuclear Power

View source version on businesswire.com: http://www.businesswire.com/news/home/20160919006203/en/

Business Wire
www.businesswire.com

Last updated on: 19/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.